NuCana (NCNA) Reports Promising Clinical Data at ASCO GI on NUC-1031 as Front-Line Treatment of Advanced Biliary Tract Cancer
Tweet Send to a Friend
NuCana plc (NASDAQ: NCNA) announced interim results today from the ABC-08 Study at the 2018 ASCO Gastrointestinal Cancer Symposium (ASCO ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
